Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629551 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
NCT00629551: Completed Phase 3 study, sponsored by Sanofi.
NCT00629551 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 825 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00629551, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in patients with major depressive disorder. The study also includes a double-placebo group (saredutant placebo in combination with paroxetine placebo).
Interventions
- DRUG placebo
- DRUG paroxetine
- DRUG saredutant (SR48968)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00629551 record still lists
NCT00629551 is an interventional study that assigns participants to a tested intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00629551 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00629551 about?
NCT00629551 is a clinical study titled "An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder". The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in patients with major depressive disorder. The study also includes a double-...
What is the current status of trial NCT00629551?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2008-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00629551?
The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), saredutant (SR48968) (DRUG).
Who is sponsoring clinical trial NCT00629551?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00629551's enrollment target sits among peer trials
825 400th of 2000 higher than 1,599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia